Literature DB >> 14529790

The linear-quadratic model and fractionated stereotactic radiotherapy.

Lizhong Liu1, Daniel A Bassano, Satish C Prasad, Seung S Hahn, Chung T Chung.   

Abstract

PURPOSE: To determine the dose per fraction that could be used when gamma knife or linear accelerator-based stereotactic treatments are delivered in 2 or more fractions. METHODS AND MATERIALS: The linear-quadratic (LQ) model was used to calculate the dose per fraction for a multiple-fraction regimen which is biologically equivalent to a given single-fraction treatment. The results are summarized in lookup tables. RESULTS AND
CONCLUSION: The tables can be used by practicing clinicians as a guide in planning fractionated treatment. For the large doses used in typical stereotactic treatments and for small fraction numbers, the model is not very sensitive to the value of the alpha/beta ratio in the LQ model. A simple rule of thumb is found that for two-fraction and three-fraction treatments the dose per fraction is roughly two-thirds and one-half of the single-fraction treatment dose, respectively.

Mesh:

Year:  2003        PMID: 14529790     DOI: 10.1016/s0360-3016(03)00634-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

1.  Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).

Authors:  Silvia Scoccianti; Marco Krengli; Livia Marrazzo; Stefano Maria Magrini; Beatrice Detti; Vincenzo Fusco; Luigi Pirtoli; Daniela Doino; Alba Fiorentino; Laura Masini; Daniela Greto; Michela Buglione; Giovanni Rubino; Federico Lonardi; Fernanda Migliaccio; Salvino Marzano; Riccardo Santoni; Umberto Ricardi; Lorenzo Livi
Journal:  Radiol Med       Date:  2017-09-06       Impact factor: 3.469

2.  A modified protocol of mandibular osteoradionecrosis induction in rats with external beam radiation therapy.

Authors:  Mayra Cristina Yamasaki; Gina Delia Roque-Torres; Leonardo Vieira Peroni; Eduarda Helena Leandro Nascimento; Benjamin Salmon; Matheus Lima Oliveira; Deborah Queiroz Freitas; Lourenço Correr-Sobrinho
Journal:  Clin Oral Investig       Date:  2019-08-10       Impact factor: 3.573

3.  Optimizing the flattening filter free beam selection in RapidArc®-based stereotactic body radiotherapy for Stage I lung cancer.

Authors:  J-Y Lu; Z Lin; P-X Lin; B-T Huang
Journal:  Br J Radiol       Date:  2015-07-02       Impact factor: 3.039

4.  Long-term outcome of moderate hypofractionated stereotactic radiotherapy for meningiomas.

Authors:  Ernesto Maranzano; Lorena Draghini; Michelina Casale; Fabio Arcidiacono; Paola Anselmo; Fabio Trippa; Cesare Giorgi
Journal:  Strahlenther Onkol       Date:  2015-10-21       Impact factor: 3.621

5.  Enhanced survival and cure of F98 glioma-bearing rats following intracerebral delivery of carboplatin in combination with photon irradiation.

Authors:  Julia Rousseau; Caroline Boudou; Rolf F Barth; Jacques Balosso; François Estève; Hélène Elleaume
Journal:  Clin Cancer Res       Date:  2007-08-28       Impact factor: 12.531

6.  Isoeffect calculations with the linear quadratic and its extensions: An examination of model-dependent estimates at doses relevant to hypofractionation.

Authors:  Frederick W McKenna; Salahuddin Ahmad
Journal:  J Med Phys       Date:  2011-04

7.  Radiobiological modeling analysis of the optimal fraction scheme in patients with peripheral non-small cell lung cancer undergoing stereotactic body radiotherapy.

Authors:  Bao-Tian Huang; Jia-Yang Lu; Pei-Xian Lin; Jian-Zhou Chen; De-Rui Li; Chuang-Zhen Chen
Journal:  Sci Rep       Date:  2015-12-11       Impact factor: 4.379

8.  Is upfront stereotactic radiosurgery a rational treatment option for very elderly patients with brain metastases? A retrospective analysis of 106 consecutive patients age 80 years and older.

Authors:  Shoji Yomo; Motohiro Hayashi
Journal:  BMC Cancer       Date:  2016-12-15       Impact factor: 4.430

9.  Re-irradiation: outcome, cumulative dose and toxicity in patients retreated with stereotactic radiotherapy in the abdominal or pelvic region.

Authors:  Huda Abusaris; M Hoogeman; Joost J Nuyttens
Journal:  Technol Cancer Res Treat       Date:  2012-05-07

10.  Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer.

Authors:  Bao-Tian Huang; Zhu Lin; Pei-Xian Lin; Jia-Yang Lu; Chuang-Zhen Chen
Journal:  Oncotarget       Date:  2016-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.